| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Puliginurad targets the urate transporter (URAT), a protein responsible for reabsorbing uric acid in the kidney. URAT is a key regulator of serum uric acid levels. By inhibiting URAT, Puliginurad reduces uric acid reabsorption, increasing uric acid excretion and lowering serum uric acid levels. This mechanism makes it a potential therapeutic agent for hyperuricemia and gout.
|
|---|---|
| ln Vitro |
In vitro, Puliginurad acts as a potent and selective inhibitor of the urate transporter protein (URAT), effectively inhibiting uric acid reabsorption. It is a URAT inhibitor with the potential for hyperuricemia and gout treatment. Specific in vitro data such as IC50 values are limited in publicly available sources.
|
| ln Vivo |
In vivo, Puliginurad is used for hyperuricemia and gout research. As a URAT inhibitor, it lowers serum uric acid levels by increasing renal uric acid excretion. It has the potential for hyperuricemia and gout treatment. Specific in vivo efficacy data are limited.
|
| Enzyme Assay |
In vitro transporter assays are used to characterize Puliginurad's inhibition of URAT. Cells expressing URAT are incubated with uric acid and the compound at various concentrations. Uric acid uptake is measured using radiolabeled uric acid or colorimetric assays. Inhibition of uric acid uptake is calculated from dose-response curves.
|
| Cell Assay |
Cell-based assays for Puliginurad are conducted in cells expressing URAT. Cells are treated with the compound at various concentrations, and uric acid uptake is measured. These assays characterize the compound's potency and selectivity for URAT inhibition.
|
| Animal Protocol |
In vivo animal experiments with Puliginurad are conducted in hyperuricemic animal models. The compound is administered orally, and serum uric acid levels are measured. Uric acid excretion is assessed by measuring urinary uric acid. Efficacy is evaluated by reduction in serum uric acid levels.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Puliginurad include oral activity. The compound is designed for oral administration for hyperuricemia and gout treatment. Specific PK parameters such as half-life, Cmax, and bioavailability have not been extensively reported. Storage: appropriately.
|
| Toxicity/Toxicokinetics |
Safety and toxicology data for Puliginurad are limited. The compound is for research use only and is not approved for human therapeutic use without appropriate regulatory approval. Standard laboratory safety precautions should be followed when handling the compound.
|
| References | |
| Additional Infomation |
Puliginurad has CAS number 2013582-27-7, molecular formula C19H16N2O2S, and molecular weight 336.41. Synonyms: YL-90148. It is a potent and selective URAT inhibitor that effectively inhibits uric acid reabsorption. It can be used for hyperuricemia and gout research. Purity: typically ≥98%. Not for human use; for research purposes only.
|
| Molecular Formula |
C19H16N2O2S
|
|---|---|
| Molecular Weight |
336.407543182373
|
| Exact Mass |
336.093
|
| CAS # |
2013582-27-7
|
| PubChem CID |
122582049
|
| Appearance |
White to off-white solid powder
|
| LogP |
3.9
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
24
|
| Complexity |
519
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C(C1SC2=CN=CC(C3C=CC(C#N)=CC=3)=C2C=1)C(C)(C)C(=O)O
|
| InChi Key |
QWCZAFGDQBUAFT-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C19H16N2O2S/c1-19(2,18(22)23)8-14-7-15-16(10-21-11-17(15)24-14)13-5-3-12(9-20)4-6-13/h3-7,10-11H,8H2,1-2H3,(H,22,23)
|
| Chemical Name |
3-[4-(4-cyanophenyl)thieno[2,3-c]pyridin-2-yl]-2,2-dimethylpropanoic acid
|
| Synonyms |
YL-90148; YL90148; YL 90148
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~130 mg/mL (~386.4 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 3.25 mg/mL (9.66 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 32.5 mg/mL clear DMSO stock solution to 400 μL of PEG300 and mix evenly; then add 50 μL of Tween-80 to the above solution and mix evenly; then add 450 μL of normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 3.25 mg/mL (9.66 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 32.5 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: 3.25 mg/mL (9.66 mM) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9726 mL | 14.8628 mL | 29.7256 mL | |
| 5 mM | 0.5945 mL | 2.9726 mL | 5.9451 mL | |
| 10 mM | 0.2973 mL | 1.4863 mL | 2.9726 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
